Fertility and Sterility
Volume 89, Issue 5 , Pages 1200-1208 , May 2008

Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action

  • Vanita Aroda, M.D.

      Affiliations

    • VA San Diego Healthcare System, San Diego, California
    • Department of Medicine, University, San Diego, La Jolla, California
    • ,
  • Theodore P. Ciaraldi, Ph.D.

      Affiliations

    • VA San Diego Healthcare System, San Diego, California
    • Department of Medicine, University, San Diego, La Jolla, California
    • ,
  • Sang-Ah Chang, M.D.

      Affiliations

    • VA San Diego Healthcare System, San Diego, California
    • Department of Medicine, University, San Diego, La Jolla, California
    • ,
  • Michael H. Dahan, M.D.

      Affiliations

    • Department of Reproductive Medicine, University of California, San Diego, California
    • ,
  • R. Jeffrey Chang, M.D.

      Affiliations

    • Department of Reproductive Medicine, University of California, San Diego, California
    • ,
  • Robert R. Henry, M.D.

      Affiliations

    • VA San Diego Healthcare System, San Diego, California
    • Department of Medicine, University, San Diego, La Jolla, California
    • Corresponding Author InformationReprint requests: Robert R. Henry, M.D., VA San Diego Healthcare System, mail code 111G, 3350 La Jolla Village Drive, San Diego, CA 92161 (FAX: 858-642-6242).

Received 12 October 2006 ,Revised 24 April 2007 ,Accepted 25 April 2007.

References 

  1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endo Metabol. 1998;83:3078–3082
  2. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab. 1983;57:356–359
  3. Cattrall FR, Healy DL. Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovarian syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18:803–812
  4. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548–2556
  5. Daimon M, Oizumi T, Saitoh T, Kameda W, Hirata A, Yamaguchi H, et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population: the Funagata study. Diabetes Care. 2003;26:2015–2020
  6. Snehalatha C, Mukesh B, Simon M, Viswanathan V, Haffner SM, Ramachandran A. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care. 2003;26:3226–3229
  7. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930–1935
  8. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes. 2001;50:1126–1133
  9. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine. 2001;7:941–946
  10. Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism. 2002;51:314–317
  11. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adiponectin levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2004;89:4312–4319
  12. Yu JG, Javorschi S, Henever AL, Kruszynska YT, Norman RA, Sinha M, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese and type 2 diabetic subjects. Diabetes. 2002;51:2968–2974
  13. Phillips S, Ciaraldi T, Kong A, Bandukwala R, Aroda V, Carter L, et al. Modulation of circulating and adipose tissue adiponectin levels by anti-diabetic therapy. Diabetes. 2003;52:667–674
  14. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem. 2003;278:9073–9085
  15. Tsao T-S, Tomas E, Murrey HE, Hug C, Lee DH, Ruderman NB, et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem. 2003;278:50810–50817
  16. Orio F, Palomba S, Cascella T, Milan G, Mioni R, Pagano C, et al. Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:2619–2623
  17. Panidis D, Kourtis A, Farmakiotis D, Mouslech T, Rousso D, Koliakos G. Serum adiponectin levels in women with polycystic ovary syndrome. Hum Repro. 2003;18:1790–1796
  18. Seplilian V, Nagamani M. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance. J Soc Gynecol Invest. 2005;12:129–134
  19. Sieminska L, Marek B, Kos-Kudla B, Niedziolka D, Kajdaniuk D, Nowak M, et al. Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters. J Endocrinol Invest. 2004;27:528–534
  20. Spranger J, Mohlig M, Wegewitz U, Ristow M, Pfeiffer AFH, Schill T, et al. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol. 2004;61:738–746
  21. Xita N, Georgiou I, Chatzikyriakidou A, Vounatsou M, Papassotiriou G-P, Papassotiriou I, et al. Effect of adiponectin gene polymorphism on circulating adiponectin and insulin resistance indexes in women with polycystic ovary syndrome. Clin Chem. 2005;51:416–423
  22. Lane DE. Polycystic ovary syndrome and its differential diagnosis. Obstet Gynecol Surv. 2006;61:125–135
  23. Coffler MS, Patel KD, M.H., Yoo RY, Malcom PJ, Chang RJ. Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone. J Clin Endo Metabol 2003;88:5624–31.
  24. American Diabetes Association . Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27:S5–S10
  25. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J. Physiol. 1979;237:E214–E223
  26. Thornburn AW, Gumbiner B, Bulacan F, Wallace P, Henry RR. Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin dependent (type II) diabetes independent of impaired glucose uptake. J Clin Invest. 1990;85:522–529
  27. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;27:680–685
  28. Ciaraldi TP, Kolterman OG, Scarlett JA, Kao M, Olefsky JM. Role of glucose transport in the post-receptor defect of non-insulin dependent diabetes mellitus. Diabetes. 1982;31:1016–1022
  29. Rodbell M. Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem. 1964;239:375–380
  30. Thies RS, Molina JM, Ciaraldi TP, Freidenberg GR, Olefsky JM. Insulin-receptor autophosphorylation and endogenous substrate phosphorylation in human adipocytes from control, obese, and NIDDM subjects. Diabetes. 1990;39:250–259
  31. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, et al. Impaired multimerization of human adiponectin mutants associated with diabetes: molecular structure and multimer formation of adiponectin. J Biol Chem. 2003;278:40352–40363
  32. Peake PW, Kriketos AD, Campbell IV, Shen Y, Charlesworth JA. The metabolism of isoforms of human adiponectin: studies in human subjects and in experimental animals. Eur J Endocrinol. 2005;153:409–417
  33. Bodles A, Banga A, Rasouli N, Ono F, Kern PA, Owens RJ. Pioglitazone increases secretion of high molecular weight adiponectin from adipocytes. Am J Physiol Endocrinol Metab. 2006;291:E1100–E1105
  34. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun. 1996;221:286–289
  35. Das K, Lin Y, Wilden E, Zhang Y, Scherer PE. Chromosomal localization, expression patters, and promoter analysis of the mouse gene encoding adipocyte-specific secretory protein Acrp30. Biochem Biophys Res Commun. 2001;280:1120–1129
  36. Scherer PE, Williams S, Fogliano MF, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270:26746–26749
  37. Duncan Bb, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM, et al. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2004;53:2473–2478
  38. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PT, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 2002;360:57–58
  39. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes. 2002;51:2734–2741
  40. Fisher FM, McTernan PG, Valsamakis G, Chetty R, Harte AL, Anwar AJ, et al. Differences in adiponectin protein expression: effect of fat depots and type 2 diabetic status. Horm Metab Res. 2002;34:650–654
  41. Bottner A, Kratzsch J, Muller G, Kapellen TM, Bluher S, Keller E, et al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endo Metabol. 2004;89:4053–4061
  42. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity J. Biol Chem. 2004;279:12152–12162
  43. Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, et al. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunoabsorbent assay to detect HMW adiponectin. Diabetes. 2006;55:1954–1960
  44. Xu A, Chan KW, Hoo RLC, Wang Y, Tan KCB, Zhang J, et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem. 2005;280:18073–18080

 Present address of Dr. Sang-Ah Chang: Department of Internal Medicine, Catholic University of Korea, Seoul, Korea.

 Present address of Dr. Michael H. Dahan: Department of Obstetrics and Gynecology, Stanford University, 300 Pasteur Dr., Stanford, CA 94305.

 R.R.H. is a consultant, member of the advisory board, and has received a research grant from Takeda Pharmaceuticals North America.

 Supported by the Department of Veterans Affairs, the VA San Diego Healthcare System, the American Diabetes Association (T.P.C., R.R.H.), American Diabetes Association Mentor-based Fellowship (R.R.H.), NIH ROI-DK-258291 (R.R.H.), National Institute of Child Health and Human Development/National Institutes of Health through cooperative agreement (U54 HD 12303-20) as part of the Specialized Cooperative Centers Program in Reproduction Research (R.J.C.), Takeda Pharmaceuticals North America (R.R.H.), and grant MO1 RR-00827 from the General Clinical Research Branch, Division of Research Resources, National Institutes of Health.

 Presented at 64th Scientific Sessions of the American Diabetes Association, Orlando, Florida, June 4–8, 2004.

PII: S0015-0282(07)01012-6

doi: 10.1016/j.fertnstert.2007.04.046

Fertility and Sterility
Volume 89, Issue 5 , Pages 1200-1208 , May 2008

Article Tools

* Image Usage & Resolution